For Year 2025-26, Eris Lifesciences reports the following shareholding: Total Promoters at 54.85%, Mutual Fund at 18.26%, Insurance at 1.25%, Foreign Institutional Investors at 6.85%, Domestic Institutional Investors at 0.81%, and Retail at 17.99%. This breakdown provides a quick snapshot of ownership distribution for Eris Lifesciences in 2025-26.